Charles River Laboratories | CRL - Debt


Charles River Laboratories reported $2.63B in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Agilent USD 3.35B 55M Sep/2025
Align Technology USD 121.27M 1.75M Sep/2025
Bio-Rad Laboratories USD 1.4B 11.2M Sep/2025
Bruker USD 2.01B 426.8M Sep/2025
Cardinal Health USD 9.03B 505M Sep/2025
Charles River Laboratories USD 2.63B 157.4M Sep/2025
Cigna USD 34.04B 3.27B Sep/2025
Concord Medical Services Hldg CNY 3.01B 27.15M Jun/2023
CVS Health USD 64.57B 1.27B Dec/2025
Danaher USD 18.42B 1.56B Dec/2025
Dentsply International USD 2.48B 14M Sep/2025
Elevance Health USD 32.05B 56M Dec/2025
Galapagos EUR 7.5M 3.36M Sep/2025
Hologic USD 2.63B 104.3M Sep/2025
Humana USD 12.37B 238M Dec/2025
Illumina USD 2.58B 22M Sep/2025
Incyte USD 40.41M 855K Dec/2025
Intrexon USD 0 13.82M Jun/2024
IQVIA Holdings USD 15.72B 767M Dec/2025
Laboratory Of America USD 6.53B 16.1M Sep/2025
Lonza CHF 4.71B 915M Dec/2024
McKesson USD 9.79B 141M Sep/2025
Merck EUR 9.4B 704M Jun/2025
Mettler Toledo International USD 2.21B 25.94M Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Pfizer USD 60.85B 78M Sep/2025
Quest Diagnostics USD 6.38B 2M Sep/2025
Revvity USD 3.37B 5.86M Sep/2025
Thermo Fisher Scientific USD 35.68B 451M Sep/2025
United Therapeutics USD 200M 100M Mar/2025
UnitedHealth USD 78.39B 1.75B Dec/2025
Veradigm USD 200.33M 431K Sep/2022
Waters USD 1.49B 52.2M Sep/2025
West Pharmaceutical Services USD 202.8M 100K Dec/2025